| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Editorial Lp(a) – the underestimated cardiovascular risk factor
|
Mellwig, Klaus-Peter
|
|
2017
|
12 |
supplement-1 |
p. 1
|
artikel
|
| 2 |
Hyperlipoproteinaemia(a) – apheresis and emerging therapies
|
Vogt, Anja
|
|
2017
|
12 |
supplement-1 |
p. 12-17
|
artikel
|
| 3 |
Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease
|
van Buuren, Frank
|
|
2017
|
12 |
supplement-1 |
p. 55-59
|
artikel
|
| 4 |
Lipoprotein (a) and coronary heart disease – is there an efficient secondary prevention?
|
Mellwig, Klaus-Peter
|
|
2017
|
12 |
supplement-1 |
p. 18-21
|
artikel
|
| 5 |
Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies
|
Orsó, Evelyn
|
|
2017
|
12 |
supplement-1 |
p. 31-37
|
artikel
|
| 6 |
Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis
|
Heigl, Franz
|
|
2017
|
12 |
supplement-1 |
p. 50-54
|
artikel
|
| 7 |
Lipoprotein(a) in nephrological patients
|
Hohenstein, Bernd
|
|
2017
|
12 |
supplement-1 |
p. 27-30
|
artikel
|
| 8 |
PCSK9 targets important for lipid metabolism
|
Schulz, Rainer
|
|
2017
|
12 |
supplement-1 |
p. 2-11
|
artikel
|
| 9 |
Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines
|
Klingel, Reinhard
|
|
2017
|
12 |
supplement-1 |
p. 38-43
|
artikel
|
| 10 |
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
|
Grützmacher, P.
|
|
2017
|
12 |
supplement-1 |
p. 22-26
|
artikel
|
| 11 |
The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on
|
Schettler, V. J. J.
|
|
2017
|
12 |
supplement-1 |
p. 44-49
|
artikel
|
Tijdschrift beschrijving